China Tumor Embolization Report

September 2022

China Tumor Embolization report is the first ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Radiology, Vascular Surgery and General Surgery departments from Level 2 and Level 3 hospitals in China.

The report covers:

Tumor embolization devices: Bland embolization/transarterial chemoembolization, DEB-TACE, Radio Embolization (Y90), Coil/Microcoil embolization, nBCA or Onyx.
Procedure trends: cancer type and modality/device type

“Liquid embolization is commonly used, mainly the iodinated oil. We also use PV particles, which is polyethylene, blank microsphere and drug carrying microspheres. Many companies are producing drug carrying microsphere now, some are multi-drug carrying and some are single drug carrying. Drug carrying microsphere is the best embolization type now, it’s like continuous infusion chemotherapy, where the drug is continuously reaching the tumor.”

– Interventional Radiologist, Tumor Embolization China

>60% of all tumor embolization procedures are performed on liver cancers
~61% of all tumor embolization procedures are performed using bland embolization/TACE
~60% of Interventional Radiologists preferred combination therapy using embolization and chemotherapy

Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.Future trends such as immunotherapy used in combination with embolization technologies is gaining prominence. Expanded indications of embolization to treat cancer types such as prostate cancer and cholangiocarcinoma is expected to increase as clinical evidence suggests good patient outcomes.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as recent NMPA approval of Sirtex Medical’s SIR-Sphere Y-90 resin microsphere for treatment of patients with colorectal cancer liver metastasis; China Grand Pharmaceutical’s acquisition of rights from Shenming Medical Technology Company of an innovative thermosensitive embolic agent for the treatment of liver cancer are covered in the report.

What’s in it for you?

This report will help tumor embolization devices companies understand the interventional oncology landscape, procedural and technology trends, the brand perception, and competitor activities in China.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the tumor embolization devices market.

The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model.
REPORT COST: 5,000 USD
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.

China Tumor Embolization Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2019-2022)

Privacy settings